Pricing Log in Create free account
Friday 6 November 2026 Export MDT’s income statement to Excel — free account

Medtronic PLC

MDT Healthcare Medical Devices

Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025.

Revenue
+13.7%
EPS
+42.0%
Free cash flow
+120.9%
Total debt
−1.59%

Quarter to July 2026, against a year earlier

102.26 2.58 −2.46%
Market cap
$134.1B
P/E
25.6×
Fwd P/E
20.8×
Dividend yield
2.74%
F-score
7/9
Altman Z
2.73
Beneish M
−2.58
Dividend safety
61/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Medtronic PLC (MDT) Earnings & Analysis

Updated · Covers results through Q1 FY2027 · How this is made

Latest quarter

Medtronic reported Q1 FY2027 revenue of $9.8 billion, up 13.7% from Q1 FY2026, while revenue as the consensus counts it was $9.8 billion versus consensus revenue of $9.5 billion. The company reported adjusted EPS, as the consensus counts it, of $1.45, compared with consensus adjusted EPS of $1.39; its reported diluted EPS was $1.14, up 40.7% from $0.81 a year earlier.

The filing attributed sales growth partly to growth across most businesses, an extra week in the first fiscal month with an estimated $570 million benefit to reported growth, and foreign-currency fluctuations. Cardiovascular sales were $3.9 billion and increased 20%; Neuroscience sales were $2.7 billion and increased 10%; and Medical Surgical sales were $2.3 billion and increased 10%. The filing reported gross margin of 65.0%, unchanged from a year earlier, and operating margin of 18.1%, compared with 16.8%. Medtronic reported free cash flow of $1.3 billion, up 120.9% from $584.0 million.

Q1 FY2027 Q1 FY2026 Change
Revenue $9.8 billion $8.6 billion 13.7%
Diluted EPS $1.14 $0.81 40.7%
Gross margin 65.0% 65.0% 0.0 percentage points
Operating margin 18.1% 16.8% 1.2 percentage points
Free cash flow $1.3 billion $584.0 million 120.9%
Against the consensus Reported Consensus Result
Adjusted EPS $1.45 $1.39 Beat by 4.32%
Revenue $9.8 billion $9.5 billion Beat by 3.01%

Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.

What management said on the call

No earnings call was available, so Medtronic did not provide call commentary or answers to analyst questions for this page.

Guidance

Medtronic raised its FY2027 organic revenue growth guidance to 7.25% to 7.75% from prior guidance of 6.75% to 7.25%. The company also raised FY2027 diluted non-GAAP EPS guidance to $5.94 to $6.00 from the prior range of $5.90 to $6.00.

Metric For Guide Previous guide Change
EPS, non-GAAP FY2027 $5.94–$6.00 — New
Revenue growth, Organic FY2027 7.25%–7.75% — New

This page is for information only. It is not investment advice, a recommendation or an offer to buy or sell any security. Figures come from the sources listed above and may contain errors; verify against the company's filings.